• S J Donohue, A Midgley, J C Davies, R D Wright, I Bruce, M W Beresford, C M Hedrich, MRC MASTERPLANS Consortium, and UK jSLE Cohort Study and Repository.
• Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
• Clin. Immunol. 2020 May 1; 214: 108375.

AbstractUp to 80% of juvenile-onset systemic lupus erythematosus (jSLE) patients develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably diagnose LN, leaving kidney biopsies as the gold-standard. Calcium-binding S100 proteins are expressed by innate immune cells and epithelia and may act as biomarkers in systemic inflammatory conditions. We quantified S100 proteins in the serum and urine of jSLE patients, matched healthy and inflammatory (IgA vasculitis) controls. Serum S100A8/A9, and serum and urine S100A12 are increased in jSLE patients when compared to controls. Furthermore, serum S100A8/A9, and serum and urine S100A12 are increased in jSLE patients with active as compared to patients with inactive/no LN. No differences in S100A4 levels were seen between groups. This study demonstrates potential promise for S100A8/A9 and S100A12 as biomarkers for jSLE and active LN. Findings require to be confirmed and tested prospectively in independent and larger multi-ethnic cohorts.Copyright © 2020 Elsevier Inc. All rights reserved.

36 keywords...

hide…